Sarcomatoid RCC – molecular features and new opportunities for treatment

Sarcomatoid renal cell carcinoma (RCC) is difficult to treat and has long been associated with a poor prognosis. Also, the biology of sarcomatoid RCC has remained obscure. Scientists have tried to determine the molecular profile of sarcomatoid RCC and investigate different targeted therapies for genes such as TP53,┬áBAP1, cell cycle, and chromatin-remodelling genes. Investigation of […]

read more

The future of immunotherapy-based combinations for metastatic kidney cancer

The past decade or so has seen the development of multiple targeted therapies for metastatic renal cell carcinoma (RCC), such as vascular endothelial growth factor (VEGF) inhibitors and inhibitors of the mammalian target of rapamycin (mTOR) pathway. Most recently, immune checkpoint inhibitors have been shown to have excellent clinical efficacy. Although patients are living longer, […]

read more

Molecular genetics of renal cell carcinoma

Most renal cell carcinomas (RCC) are diagnosed from studying the cells from a biopsy under a microscope (histology findings), with and without the use of antibodies to check for certain proteins in the tumour tissue (immunohistochemical examination). RCC tumours are very heterogeneous – there are many subtypes of RCC which have different appearances under the […]

read more

Non-cancer drugs tested on cancer cells

Scientists at the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard and Dana-Farber Cancer Institute in the USA have tested thousands of non-cancer medicines in hundreds of different types of cancer cell in the laboratory to see if they can be used to treat cancer. They tested drugs that are currently licensed to […]

read more

Scientists discover a part of the immune system that may be used to treat all cancers

Scientists from the University of Cardiff have discovered part of our immune system that could potentially be harnessed to treat all types of cancer. This potential treatment has not yet been tested in humans, but has been shown to kill prostate, breast, lung and other cancers in the laboratory. Researchers suggest that the treatment has […]

read more

Rational approaches to treatment duration with immunotherapy for kidney cancer

A recent review of the use of immune checkpoint inhibitors for the treatment of metastatic renal cell carcinoma (RCC) was published in European Urology Focus this month. The use of immune checkpoint inhibitors has revolutionised the treatment of metastatic RCC over recent years. However, the appropriate duration of treatment with immune checkpoint inhibitors, such as […]

read more

Percutaneous ablation for small renal masses

Current guidelines recommend partial nephrectomy as the preferred treatment option for small renal masses. Percutaneous ablation, such as radiofrequency ablation and cryoablation, are mainly considered for patients who are not suitable for surgery or who have other conditions (co-morbidities) that make them unfit for surgery. There is currently a lack of evidence comparing partial nephrectomy […]

read more

Assessing and managing adverse events to immunotherapies

In this video interview, Brenda Martone discusses the clinical nurse specialist’s role in assessing and managing immune-related complications and toxicities associated with immune checkpoint inhibitors, such as nivolumab, ipilimumab and pembrolizumab. Brenda notes that immune-related reactions may occur months after a single dose of the immune checkpoint inhibitors. Immune-related reactions may include diarrhoea and colitis, […]

read more

Long term survival after radiofrequency ablation for kidney cancer

A study published in the Journal of Vascular and Interventional Radiology looked at the long-term survival benefits from radiofrequency ablation (RFA) in patients with localised renal cell carcinoma (RCC). The outcomes of 100 patients with localised RCC (kidney cancer that has not spread) were looked at retrospectively. All patients had percutaneous radiofrequency ablation and were […]

read more

C-reactive protein as a potential predictive biomarker for kidney cancer

A recent study published in Science Direct describes how a change in blood C-reactive protein (CRP) levels during the early phase of nivolumab treatment for metastatic renal cell carcinoma (mRCC) may be used to predict survival among patients with mRCC. Read more in Science Direct here

read more
Showing 1 to 10 of 698 results
  TOP